[ Fri, Feb 21st 2025 ]: TechCrunch
[ Fri, Feb 21st 2025 ]: IFLScience
[ Fri, Feb 21st 2025 ]: CNET
[ Fri, Feb 21st 2025 ]: kennesaw
[ Fri, Feb 21st 2025 ]: businessday
[ Fri, Feb 21st 2025 ]: businessday
[ Fri, Feb 21st 2025 ]: Reuters
[ Fri, Feb 21st 2025 ]: WKBW
[ Fri, Feb 21st 2025 ]: Forbes
[ Fri, Feb 21st 2025 ]: SpaceNews
[ Fri, Feb 21st 2025 ]: cnbctv18
[ Fri, Feb 21st 2025 ]: NextBigFuture
[ Fri, Feb 21st 2025 ]: Zawya
[ Fri, Feb 21st 2025 ]: Zawya
[ Fri, Feb 21st 2025 ]: MSN
[ Fri, Feb 21st 2025 ]: MSN
[ Thu, Feb 20th 2025 ]: Investopedia
[ Thu, Feb 20th 2025 ]: SignalSCV
[ Thu, Feb 20th 2025 ]: Reuters
[ Thu, Feb 20th 2025 ]: BBC
[ Thu, Feb 20th 2025 ]: NextBigFuture
[ Thu, Feb 20th 2025 ]: Politico
[ Thu, Feb 20th 2025 ]: techUK
[ Thu, Feb 20th 2025 ]: GeekWire
[ Thu, Feb 20th 2025 ]: Nature
[ Thu, Feb 20th 2025 ]: Wired
[ Thu, Feb 20th 2025 ]: digitalcameraworld
[ Thu, Feb 20th 2025 ]: manilatimes
[ Thu, Feb 20th 2025 ]: Yahoo
[ Thu, Feb 20th 2025 ]: Forbes
[ Thu, Feb 20th 2025 ]: AZoCleantech
[ Thu, Feb 20th 2025 ]: MSN
[ Thu, Feb 20th 2025 ]: MSN
[ Thu, Feb 20th 2025 ]: Zawya
[ Wed, Feb 19th 2025 ]: Yahoo
[ Wed, Feb 19th 2025 ]: WCJB
[ Wed, Feb 19th 2025 ]: kpax
[ Wed, Feb 19th 2025 ]: MLive
[ Wed, Feb 19th 2025 ]: NextBigFuture
[ Wed, Feb 19th 2025 ]: ABC
[ Wed, Feb 19th 2025 ]: Chronicle
[ Wed, Feb 19th 2025 ]: TechCrunch
[ Wed, Feb 19th 2025 ]: Inc
[ Wed, Feb 19th 2025 ]: Zawya
[ Wed, Feb 19th 2025 ]: news10nbc
[ Wed, Feb 19th 2025 ]: MSN
[ Wed, Feb 19th 2025 ]: ProPakistani
[ Wed, Feb 19th 2025 ]: Forbes
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
- 🞛 This publication is a summary or evaluation of another publication
- 🞛 This publication contains editorial commentary or bias from the source
- 🞛 This publication contains potentially derogatory content such as foul language or violent themes
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval SINGAPORE,

Read the Full manilatimes Article at:
[ https://www.manilatimes.net/2025/02/21/tmt-newswire/pr-newswire/first-and-only-treatment-for-chronic-hypoparathyroidism-approved-in-australia/2059832 ]